Zhuoqiao Li

Title: Innovations of Zhuoqiao Li in Anti-Colitis Drug Development

Introduction

Zhuoqiao Li is an accomplished inventor based in Changchun, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for inflammatory bowel disease. His innovative work has the potential to improve the quality of life for many patients suffering from colitis.

Latest Patents

Zhuoqiao Li holds a patent for the "Use of oleanolic acid-28-O-beta-D-glucopyranoside in preparation of anti-colitis drug." This patent highlights the use of oleanolic acid-28-O-β-D-glucopyranoside, which exhibits significant anti-ulcerative-colitis activity compared to its parent compound, oleanolic acid, and other analogues. The efficacy of this compound is comparable to Mesalazine, a first-line treatment for inflammatory bowel disease, while also minimizing the risk of salicylic acid anaphylaxis associated with Mesalazine treatment. This innovation presents a promising application prospect in the pharmaceutical industry.

Career Highlights

Zhuoqiao Li is affiliated with Jilin University, where he conducts research and development in the field of medicinal chemistry. His work has led to advancements in drug formulations that target specific health issues, showcasing his dedication to improving patient outcomes through innovative solutions.

Collaborations

Zhuoqiao Li collaborates with talented colleagues, including Junzhe Wu and Haoming Lv. Their combined expertise fosters a productive research environment that enhances the development of new therapeutic strategies.

Conclusion

Zhuoqiao Li's contributions to the field of anti-colitis drug development exemplify the impact of innovative research in medicine. His patent on oleanolic acid-28-O-β-D-glucopyranoside represents a significant advancement in treatment options for patients with inflammatory bowel disease.